SynthesisJournal of robotic surgery2026
Robotic pancreaticoduodenectomy with venous resection and reconstruction: a systematic review of perioperative, vascular, oncological and survival outcomes.
Synthesis in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robotic pancreaticoduodenectomy with venous resection and reconstruction (RPD-VR) is one of the most technically challenging procedures in hepatopancreaticobiliary surgery. While acceptance of robotic pancreaticoduodenectomy is growing, the safety, feasibility, and oncologic adequacy of combined portal vein (PV) and/or superior mesenteric vein (SMV) resection remain incompletely defined. A systematic review was conducted following PRISMA guidelines. PubMed/MEDLINE, Scopus and the Cochrane Library were searched from inception of the databases to June 2026. The Newcastle-Ottawa Scale was used to evaluate methodological quality. Twelve retrospective studies involving 202 patients undergoing RPD-VR were included. Indications were predominantly pancreatic ductal adenocarcinoma, but other periampullary and pancreatic malignancies were included. The venous reconstruction techniques were primary venorrhaphy, patch venoplasty, end-to-end anastomosis and interposition graft reconstruction. The conversion rates ranged from 0% to 36.4%. Major postoperative complications (Clavien-Dindo ≥ III) were 0% to 40%, postoperative pancreatic fistula 0% to 20% and mortality 0% to 14.3%. R0 resection rates ranged from 69.2 to 100% and lymph node harvest from 14.3 ± 6.7 to 60.0 ± 13.9 nodes. Limited long-term data suggested vascular patency rates exceeding 90% in the studies reporting follow-up imaging. Overall survival, disease-free survival and recurrence outcomes were, however, reported to a limited extent and heterogeneously across studies. Existing data suggest RPD-VR is technically feasible and may be associated with acceptable perioperative, vascular, and oncologic outcomes in carefully selected patients treated at experienced centers. However, the currently available evidence is limited by the retrospective study designs, small sample sizes, and lack of long-term oncologic follow-up. Standardised reporting and solid long-term outcome assessment in prospective multicenter studies are needed to better define the role of RPD-VR in contemporary pancreatic surgery. Prospero ID: CRD420261417822.
Indexed as
Identifiers
42474838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.